Open Exploration maintains a neutral stance on jurisdictional claims in published institutional affiliations and maps. All opinions expressed in this article are the personal views of the author(s) and do not represent the stance of the editorial team or the publisher.
References
Ahata B, Akçapınar GB. CCHFV vaccine development, current challenges, limitations, and future directions.Front Immunol. 2023;14:1238882. [DOI] [PubMed] [PMC]
Akıncı E, Bodur H, Leblebicioglu H. Pathogenesis of Crimean-Congo hemorrhagic fever.Vector Borne Zoonotic Dis. 2013;13:429–37. [DOI] [PubMed]
Robinson MW, Harmon C, O’Farrelly C. Liver immunology and its role in inflammation and homeostasis.Cell Mol Immunol. 2016;13:267–76. [DOI] [PubMed] [PMC]
Altunok S, Erdogan M, Ozkul A. Evaluation of Nucleoprotein-Based Multiepitope DNA Vaccine Constructs Against CCHFV: Insights from Immunoinformatics and In Vivo Challenges.Appl Biosci. 2026;5:25. [DOI]
Appannanavar SB, Mishra B. An update on crimean congo hemorrhagic Fever.J Glob Infect Dis. 2011;3:285–92. [DOI] [PubMed] [PMC]
Beyer D, Hoff J, Sommerfeld O, Zipprich A, Gaßler N, Press AT. The liver in sepsis: molecular mechanism of liver failure and their potential for clinical translation.Mol Med. 2022;28:84. [DOI] [PubMed] [PMC]
Chapman NS, Borisevich V, Kose N, Myers L, Priest S, Bergeron É, et al. Human antibody targeting Crimean-Congo hemorrhagic fever virus glycoprotein 38 protects mice against heterologous virus challenge.J Clin Invest. 2026;136:e191440. [DOI] [PubMed] [PMC]
Ali Dakhil A, Saleh WMM, Al-Taher SSH. Crimean-Congo Hemorrhagic Fever (CCHF): An integrated overview.Vet Integr Sci. 2025;24:1–20. [DOI]
El‐Serag HB. Epidemiology of hepatocellular carcinoma. In: Arias IM, Alter HJ, Boyer JL, Cohen DE, Shafritz DA, Thorgeirsson SS, et al., editors. The liver: Biology and pathobiology, Sixth Edition. John Wiley & Sons Ltd.; 2020. pp. 758–72. [DOI]
Flórez-Álvarez L, de Souza EE, Botosso VF, de Oliveira DBL, Ho PL, Taborda CP, et al. Hemorrhagic fever viruses: Pathogenesis, therapeutics, and emerging and re-emerging potential.Front Microbiol. 2022;13:1040093. [DOI] [PubMed] [PMC]
Frias-Staheli N, Giannakopoulos NV, Kikkert M, Taylor SL, Bridgen A, Paragas J, et al. Ovarian tumor domain-containing viral proteases evade ubiquitin- and ISG15-dependent innate immune responses.Cell Host Microbe. 2007;2:404–16. [DOI] [PubMed] [PMC]
Gautam A, Zhong L, Ogire E, Bodoirat S, Riedmiller I, Sander WJ, et al. The Crimean-Congo haemorrhagic fever virus hijacks the liver lipid metabolic pathway for virion production.Emerg Microbes Infect. 2026;15:2645855. [DOI] [PubMed] [PMC]
Grivennikov SI, Greten FR, Karin M. Immunity, inflammation, and cancer.Cell. 2010;140:883–99. [DOI] [PubMed] [PMC]
Güllü D, Keske Ş, Ergönül Ö. Viral hemorrhagic fevers—therapeutic trial advances and challenges.Expert Rev Anti Infect Ther. 2025;23:1235–50. [DOI] [PubMed]
Pirincal A, Doymaz MZ. The Role of Nucleocapsid Protein (NP) in the Immunology of Crimean-Congo Hemorrhagic Fever Virus (CCHFV).Viruses. 2024;16:1547. [DOI] [PubMed] [PMC]
Deyde VM, Khristova ML, Rollin PE, Ksiazek TG, Nichol ST. Crimean-Congo hemorrhagic fever virus genomics and global diversity.J Virol. 2006;80:8834–42. [DOI] [PubMed] [PMC]
Hawman DW, Feldmann H. Recent advances in understanding Crimean-Congo hemorrhagic fever virus.F1000Res. 2018;7:F1000 Faculty Rev–1715. [DOI] [PubMed] [PMC]
Hawman DW, Ahlén G, Appelberg KS, Meade-White K, Hanley PW, Scott D, et al. A DNA-based vaccine protects against Crimean-Congo haemorrhagic fever virus disease in a Cynomolgus macaque model.Nat Microbiol. 2021;6:187–95. [DOI] [PubMed] [PMC]
Hawman DW, Meade-White K, Leventhal S, Appelberg S, Ahlén G, Nikouyan N, et al. Accelerated DNA vaccine regimen provides protection against Crimean-Congo hemorrhagic fever virus challenge in a macaque model.Mol Ther. 2023;31:387–97. [DOI] [PubMed] [PMC]
Echanove Juan JA. Development of a novel DNA vaccine platform using viral- and vector-derived antigens to prevent Crimean-Congo hemorrhagic fever [dissertation]. Québec (QC): Université Laval; 2022.
Karanam SK, Nagvishnu K, Uppala PK, Edhi S, Varri SR. Crimean-Congo hemorrhagic fever: Pathogenesis, transmission and public health challenges.World J Virol. 2025;14:100003. [DOI] [PubMed] [PMC]
Karin M, Greten FR. NF-kappaB: linking inflammation and immunity to cancer development and progression.Nat Rev Immunol. 2005;5:749–59. [DOI] [PubMed]
Kenchegowda D, Carey BD, Shamblin J, Fitzpatrick CJ, Porier DL, Coyne S, et al. Dynamic Changes in Host Immune Response During Crimean-Congo Hemorrhagic Fever and Severe Fever with Thrombocytopenia Syndrome in Mice.Viruses. 2026;18:504. [DOI] [PubMed] [PMC]
Liu Y, Li L, Liu K, Chen S, Wu F, Li J, et al. Targeting the ICAM-1/LFA-1 adhesion axis attenuates lethal Crimean-Congo hemorrhagic fever virus infection.Cell Insight. 2026;5:100326. [DOI] [PubMed] [PMC]
Lombe BP, Munyeku-Bazitama Y, Kashitu-Mujinga G, Mukadi PK, Mampasi H, Tshilenge CGM, et al. Seroprevalence of Crimean-Congo Hemorrhagic Fever Virus Infection in Humans and Domestic Ruminants, Democratic Republic of the Congo.Emerg Infect Dis. 2026;32:543–52. [DOI] [PubMed] [PMC]
Ma HW, Ye W, Chen HS, Nie TJ, Cheng LF, Zhang L, et al. In-Cell Western Assays to Evaluate Hantaan Virus Replication as a Novel Approach to Screen Antiviral Molecules and Detect Neutralizing Antibody Titers.Front Cell Infect Microbiol. 2017;7:269. [DOI] [PubMed] [PMC]
McDuffie D, Barr D, Agarwal A, Thomas E. Physiologically relevant microsystems to study viral infection in the human liver.Front Microbiol. 2022;13:999366. [DOI] [PubMed] [PMC]
McFadden E, Monticelli SR, Wang A, Ramamohan AR, Batchelor TG, Kuehne AI, et al. Engineering and structures of Crimean-Congo hemorrhagic fever virus glycoprotein complexes.Cell. 2025;188:303–15.e13. [DOI] [PubMed] [PMC]
Fontana RJ, Liou I, Reuben A, Suzuki A, Fiel MI, Lee W, et al. AASLD practice guidance on drug, herbal, and dietary supplement-induced liver injury.Hepatology. 2023;77:1036–65. [DOI] [PubMed] [PMC]
Pirincal A, Cetin NSG, Sumbul B, Daskaya H, Durdu B, Doymaz MZ. A non-fatal Crimean-Congo hemorrhagic fever virus infection; The balanced cytokine responses on the outcome of the clinical disease.Diagn Microbiol Infect Dis. 2026;114:117145. [DOI] [PubMed]
Polanco C, Uversky VN, Huberman A, Pimentel-Hernández C, Castro MR, Hernández-Lemus E, et al. Bioinformatics Characteristics and Genomic Patterns of the Envelope Glycoproteins of the Crimean-congo Hemorrhagic Fever Viruses.Curr Anal Chem. 2025;21:106–23. [DOI]
Lee WM. Acute liver failure.Semin Respir Crit Care Med. 2012;33:36–45. [DOI] [PubMed]
Lee WM, Hynan LS, Rossaro L, Fontana RJ, Stravitz RT, Larson AM, et al.; Acute Liver Failure Study Group. Intravenous N-acetylcysteine improves transplant-free survival in early stage non-acetaminophen acute liver failure.Gastroenterology. 2009;137:856–64, 864.e1. [DOI] [PubMed] [PMC]
Taniguchi K, Karin M. NF-κB, inflammation, immunity and cancer: coming of age.Nat Rev Immunol. 2018;18:309–24. [DOI] [PubMed]
Chaudhuri O, Cooper-White J, Janmey PA, Mooney DJ, Shenoy VB. Effects of extracellular matrix viscoelasticity on cellular behaviour.Nature. 2020;584:535–46. [DOI] [PubMed] [PMC]
Lampi MC, Reinhart-King CA. Targeting extracellular matrix stiffness to attenuate disease: From molecular mechanisms to clinical trials.Sci Transl Med. 2018;10:eaao0475. [DOI] [PubMed]
Yoshikawa R, Sakurai Y, Kondo S, Kimura M, Yasuda J. Crimean-Congo hemorrhagic fever virus NSm protein inhibits the type I interferon signaling by binding to STAT2.PLoS Negl Trop Dis. 2025;19:e0013695. [DOI] [PubMed] [PMC]
